Combo Therapy May Be Advance Against Liver Cancer
MONDAY, May 6, 2024 (HealthDay News) — A new combination therapy appears to boost the response rate for liver cancer patients receiving immunotherapy, according to results from a phase 2 clinical trial. The combo therapy involves bavituximab, a drug that neutralizes a fatty substance called phosphatidylserine that cancer cells useContinue Reading